Savara Inc (SVRA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $5.39 (-0.55%), Market cap $1.05B, 52-week low–high $1.94 ~ $6.94.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Financial statements, price targets, institutional (13F) holdings and related news for Savara Inc are updated in real time on BlackAll Trade.
Savara Inc trades at $5.39 (-0.55%). Real-time quotes and charts are available on BlackAll Trade.
Savara Inc has a market cap of about $1.05B.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macroph